Izifo ze-autoimmune, eziyizinhlobo ezahlukahlukene futhi ezivame ukungezwani neziyingozi, zingenye yezindlela ezibalulekile zokuthuthukiswa kwezidakamizwa zamanje.I-JAK-STAT ingenye yezindlela ezimbalwa zokuvikela umzimba ezifakazelwe, ikakhulukazi ama-JAK inhibitors.Izidakamizwa eziningi,njenge-tofacitinib, sezimakethe emhlabeni wonke.

Inhloso ye-JAK yakhiwe isikhathi esingaphansi kweminyaka engama-20, kodwa okwamanje cishe izinhlobo eziyisi-7 sezigunyaziwe ukuthi zimakethwe.Izinkomba ikakhulukazi izimila kanye nezifo zokuzivikela komzimba, futhi izinkomba ezengeziwe ezicwengisisiwe ikakhulukazi i-bone marrow fibrosis nesifo samathambo.Okulandelayo kugxile ku-JAK inhibitor yokuqala (tofacitinib) yokwelapha isifo samathambo.

I-Tofacitinib iyi-molecule encane yomlomo i-JAK inhibitor eyakhiwe yi-Pfizer.Inokukhethwa okuhle kwe-JAK.NgoNovemba 2012, i-US FDA yagunyaza i-tofacitinib citrate yokwelashwa kwe-methotrexate impendulo enganele noma engabekezeleli ekwelashweni.Lo mkhiqizo uyi-JAK inhibitor yokuqala egunyazwe yi-FDA yokwelapha isifo samathambo.Njengamanje, ngaphezu kwezinkomba ezigunyaziwe, i-tofacitinib iphinde ihlolwe ukuthi iyasebenza yini ku-ankylosing spondylitis, i-atopic dermatitis, i-keratoconjunctivitis sicca nesifo sika-Crohn.Mayelana nokuthengiswa komhlaba wonke, ukuthengiswa kwaminyaka yonke kwe-tofacitinib ngonyaka ka-2017 bekungaphezulu kwe-US $ 1 billion, kanti ukuthengiswa konyaka ngo-2019 kufinyelele ku-US $ 2.242 billion.

Izindlela zokwenziwa ezihlukile zizoba nomthelela omkhulu ekuvunweni nakwikhwalithi yama-API.Ukuhlanganiswa kwethu kwe-tofacitinib citrate kugwema umzila onelungelo lobunikazi.Umzila wokwenziwa udinga izindleko eziphansi zezinto ezingavuthiwe, isivuno esikhulu, ukungcola okukodwa kanye nokuhlanzeka kungalawulwa ngaphakathi kwebanga elifanele, noma kungenziwa ngokwezifiso amaklayenti.Ngakho kusenza sibe nenzuzo esobala emakethe.Njengamanje umthamo wethu ungaba ngu-50kg ngenyanga, futhi i-tofacitinib citrate isivele ithunyelwe e-USA, Mexico, Franch, Bangladesh, njll.